Allergan to pay New York $200 million in opioid settlement

• Earlier this year, Johnson & Johnson reached a $230 million settlement with the state, agreeing to halt the manufacturing and sale of such drugs in New York.
• As part of the agreement, the company will also have to make information about opioids and opioid products "more accessible to the public," per the release.

What they're saying: "For more than two decades, opioids have wreaked havoc on New Yorkers and Americans across the nation — causing pain, addiction, and death," James said in a statement.

• "Our ongoing trial has been about the role companies like Allergan and its predecessors played in helping grow this epidemic, profiting while Americans suffered," she added.
• "While no amount of money will ever make up for the thousands who lost their lives or became addicted to opioids across our state, these funds will be used to prevent future devastation.”